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Abstract. Prostate carcinoma (PCa) is one of the most 
common cancers in men. Prostate-specific antigen (PSA) has 
been widely used to predict the outcome of PCa and screening 
with PSA has resulted in a decline in mortality. However, PSA 
is not an optimal prognostic tool as its sensitivity may be too 
low to reduce morbidity and mortality. Consequently, there is 
a demand for additional robust biomarkers for prostate cancer. 
Death receptor 5 (DR5) has been implicated in the prognosis 
of several cancers and it has been previously shown that it is 
negatively regulated by Yin Yang 1 (YY1) in prostate cancer 
cell lines. The present study investigated the clinical signifi-
cance of DR5 expression in a prostate cancer patient cohort and 
its correlation with YY1 expression. Immunohistochemical 
analysis of protein expression distribution was performed 
using tissue microarray constructs from 54 primary PCa and 
39 prostatic intraepithelial neoplasia (PIN) specimens. DR5 
expression was dramatically reduced as a function of higher 
tumor grade. By contrast, YY1 expression was elevated in PCa 
tumors as compared with that in PIN, and was increased with 
higher tumor grade. DR5 had an inverse correlation with YY1 
expression. Bioinformatic analyses corroborated these data. 
The present findings suggested that DR5 and YY1 expression 
levels may serve as progression biomarkers for prostate cancer.
Introduction
Prostate cancer (PCa) is the second leading cause of 
cancer‑associated mortality in the United States and the first 
in Mexico among men. PCa is the most commonly diagnosed 
cancer in males (1,2). Most PCa-associated mortalities are 
due to advanced disease, and androgen deprivation therapy is 
considered the primary approach in the treatment of symp-
tomatic advanced prostate cancer (3). This treatment option is 
palliative rather than curative and although it can marginally 
improve the likelihood of survival, the majority of all patients 
progress to hormone‑refractory PCa. The rate of PCa is highest 
among Caucasians and African‑Americans. The pathogenesis 
of PCa is very long and results in frequent hospital visits, 
which causes a high cost of treatment (4‑6).
Although the survival rates for PCa patients are high, 
because of the slow and steady nature of the disease, 30-40% 
of patients experience prostate-specific antigen (PSA) recur-
rence within 10 years of surgery or radiation treatment (7). 
Furthermore, tumor cells ultimately develop resistance to 
therapy; however, there are few alternative treatments avail-
able. Consequently, the median survival of advanced and 
recurring disease in patients with prostate cancer is drastically 
reduced (8).
An increase in circulating PSA levels following definitive 
therapy usually accurately predicts progressive disease. PSA 
can have a prognostic significance prior to therapy, since lower 
PSA levels indicate that the disease will not likely recur and 
higher levels indicate future resistance to therapy (9). PSA, 
however, is a problematic screening tool since the overall sensi-
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tivity may be too low to effectively predict mortality/survival 
rates (10). Conversely, increasing the sensitivity of PSA may 
result in false‑positive diagnosis of the disease, since the 
majority of males with PCa will die of unrelated causes (11). 
Novel PCa biomarkers are required, which should have 
the ability to distinguish between a benign and a malignant 
disease (12,13).
Apoptosis through the activation of two predominant 
pathways may be induced by the binding of ligands to specific 
receptors on the cell surface, or by non-specific cellular 
stress (14). Both pathways converge at the level of the caspases, 
which mediate cell death via cleavage of various cellular 
substrates. Death receptors (DR) 4 and 5 bind to the tumor 
necrosis factor‑related apoptosis‑inducing ligand (TRAIL), 
which results in the recruitment of the Fas-associated death 
domain (FADD) to the intracellular death domain and subse-
quently induces the cleavage of procaspase‑8 which initiates 
a cascade of events leading downstream to apoptosis (15‑18).
Reported studies have demonstrated that the surface 
expression of DR5 is a potentially useful prognostic marker 
in various cancers (19). The progression of melanoma has 
been previously associated with a decrease in DR5 and DR4 
expression (20). Furthermore, DR5, along with other TRAIL 
receptors, was shown to be useful in determining the risk of 
breast cancer metastasis and patient survival (21). However, 
other studies have shown that DR5 was not a significant prog-
nostic marker (22,23). These observations suggested that the 
prognostic value of DR5 may be cancer type-specific. In these 
cases, the role of DR5 repression in PCa was not examined.
A previous study by our group reported that the transcrip-
tion factor Yin Yang 1 (YY1) may function in the pathogenesis 
of PCa. High expression levels of YY1 were associated with 
tumor progression, and patient survival was linked to lower 
levels of YY1 (24). In addition, it was previously demonstrated 
that YY1 may transcriptionally repress DR5 expression in 
prostate cancer cell lines (25-27).
The present study investigated the expression levels of 
DR5 in PCa and its clinical significance. Since it was reported 
that YY1 negatively regulates DR5 expression and that YY1 
is overexpressed in PCa (24,25), it was hypothesized that DR5 
expression may be inhibited in PCa and may be inversely 
correlated with YY1 expression. This hypothesis was tested 
by immunohistochemistry (IHC) on tissue microarray (TMA) 
constructs, prepared with tumor tissues derived from patients 
with PCa and PIN.
Materials and methods
Patients. The study was approved by the Ethics Committee of 
the Children Hospital of Mexico ‘Federico Gomez’ (Mexico 
City, Mexico; HIM/2007/061). The study cohort consisted of 
samples from 93 randomly selected hormone-naïve patients, 
who underwent radical retropubic prostasectomy or transure-
thral resection between 2002 and 2007 from the Department 
of Pathology of Hospital General Regional No. 25, IMSS and 
Speciality Hospital CMN ‘La Raza’, IMSS (Mexico City, 
Mexico). The cohort consisted of 20 low grade PIN low grade 
(LG PIN), 19 high grade PIN (HG PIN) and 54 PCa samples. 
The 54 cases of PCa were classi fied according to the Gleason 
score as follows: 27 low‑grade prostatic carcinoma [Gleason 
score 2‑5 (LG PCa)] and 27 high‑grade prostatic carcinoma 
[Gleason score 6‑10 (HG PCa)].
P ro s t a t e  T M A  c o n s t r u c t i o n .  Fo r m a l i n - f i xe d , 
paraffin-embedded archival tumor specimens were prepared 
at the Immunology and Infection Research Unit, National 
Medical Center ‘La Raza’ and at the Oncology Disease 
Research Unit, Children Hospital of Mexico ‘Federico 
Gomez’, SSa. At least three core tissue biopsies (each 0.6 mm 
in diameter) were taken from morphologically representative 
regions of each prostate tumor and precisely arrayed as previ-
ously described (29-31). Tumor samples were accompanied by 
matching benign (morphologically normal or hyperplasic) and 
PIN lesions, where available. Tissues were arrayed into five 
TMA blocks. For staining, sections (4 µm) were transferred 
to glass slides using an adhesive slide system (PSA‑CS 4; 
Instrumedics, Inc., St. Louis, MO, USA) to support cohesion 
of the array elements.
Immunohistochemical analysis. Slices cut at 4 µm for the 
TMA were placed on slides and either stained with Mayer's 
hematoxylin and eosin (H&E) for histopathological examina-
tion, or used for subsequent immunohistochemical analysis. 
The expression levels of DR5 and YY1 were determined using 
DR5 (Abcam, Cambridge, MA, USA) and YY1 (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) antibodies. Antigen 
retrieval was performed by immersing the slides in a solution 
of 0.01% sodium citrate pH 6.0 for 5 min in boiling water. 
Endogenous peroxidase activity was inhibited by immersing 
the slides in 3% H2O2‑methanol and background-unspecific 
binding was decreased by incubating the slides in 2% bovine 
serum albumin (BSA; Sigma‑Aldrich, St. Louis, MO, USA) in 
phosphate‑buffered saline (PBS) for 60 min. The slides were 
incubated overnight at room temperature with predetermined 
optimal concentrations of anti-DR5 polyclonal antibody 
(1:500) and anti‑YY1 polyclonal antibody (1:750). In order to 
decrease variability, all samples were processed at the same 
time in a single experiment, using a single batch of antibody 
diluted in PBS‑BSA. Following washing, the slides were 
incubated with a biotinylated secondary antibody (Universal 
LSAB kit; Dako Corporation, Carpinteria, CA, USA) for 
30 min at room temperature, followed by incubation with a 
streptavidin-horseradish peroxidase conjugate (Universal 
LSAB kit) for 30 min at room temperature and then with 
3,3'‑diaminobenzidine tetra‑hydrochloride (liquid DAB, Dako 
Corporation). The reaction was stopped ny adding distilled 
water and the slides were counterstained with H&E. The 
tissue was washed in tap water for 5 min, dehydrated using an 
ethanol series (70, 90 and 100%) in xylene and mounted with 
E-2 mounting medium (Shandon lab, Pittsburgh, PA, USA). 
The slides were then analyzed by light microscopy (Olympus 
BX‑40; Olympus Corporation, Tokyo, Japan).
Scoring of immunohistochemical staining. A semi-quantita-
tive assessment of tissue antibody staining was conducted by 
an expert pathologist on prostate analysis, who was blinded to 
the pathological variables. The stained slides were verified by 
a second expert to ensure consistency in the scoring. Positive 
expression was scored based on either a positive staining on 
the membrane (DR5) or positive staining only in the nucleus 
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(YY1). Data are presented as positively stained target cells 
per 100 cells (range 0‑100% positive), per tissue region in 
the TMA (4 regions in each slide). In addition, the integrated 
optical density (IOD) in ~300 µm2 regions per sample, selected 
randomly using the Image Pro‑plus 6.4 software (Media 
Cybernetics, Bethesda, MD, USA), were analyzed.
The analysis of the expression levels on the TMAs was 
performed in a blind manner. The TMA spot was a second 
blinded quantitative assessment by the same pathologist. The 
target tissue for scoring was the glandular prostatic epithelium 
and the scoring of benign tissues did not include basal cells. 
The tissue spot histology and grading were confirmed on the 
counterstained study slides. Positive expression, indicated by a 
brown color, was quantified using the IODs. The density of the 
staining intensity in each region was analyzed using the Image 
Pro-plus 6.2  software (MediaCybernetics, Rockville, MD, 
USA) that was obtained with the diffusion of the light wave-
length through the color density in the cells stained brown. 
The target tissue for scoring was performed in the malignant 
cells by consi dering the nuclear staining pattern for YY1 and 
the membrane cytoplasmic staining pattern for DR5. YY1 
nuclear expression and DR5 cytoplasmic membrane expres-
sion were scored using two measures, negative and positive 
(weakly, moderately and strongly positive) intensities, in target 
cells. The data are presented as positively stained target cells 
per 100 cells (range 0‑100% positive), per region on each spot 
(four regions in each spot), or as density, whereby four 100 µm2 
regions per spot were selected randomly to represent expres-
sion within each case. The mean pooled integrated intensity of 
the tumor or control spots was used.
Statistical analysis. The data were analyzed using Student's 
t-test for parametric data and the Mann-Whitney test for 
non‑parametric data. To analyze normalized data, both the 
analysis of variance (ANOVA) and the Bonferroni tests were 
used. P<0.05 was considered to indicate a statistically signifi-
cant difference.
The optimal cut‑point for dichotomized PCa malignancy 
data was determined using the Gleason scoring system (32). 
The YY1‑IOD‑expression and DR5 expression were quanti-
fied by determining the sum of the IODs and the mean was 
calculated for each pathological group (malignant cells). For 
YY1 nuclear and DR‑5 cytoplasmic membrane staining, the 
percentage of positive malignant cells (weak to strong brown 
staining) was obtained. Descriptive statistics were gathered 
for all the assembled data. For differences between the patho-
logical groups that were used, Student's t test and the ANOVA 
Pearson's tests were used to analyze correlations of parametric 
data, respectively. Box plots to compare the various groups 
(central tendency, dispersion and symmetry of the data) were 
generated. P<0.05 was considered to indicate a statistically 
significant difference. All statistical analyses were performed 
using SSPS 11 statistical analysis program for Windows (SPSS 
Inc., Chicago, IL, USA) and GraphPad Prism 5.0 (GraphPad, 
San Diego, CA, USA).
Comparative metaprofiling of cDNA expression data. The 
Oncomine Premium database (Oncomine™ Compendia 
Bioscience, Ann Arbor, MI, USA) was used for analysis and visu-
alization of the bioinformatics analyses (www.oncomine.com). 
The differential expression analysis of YY1 and DR5 in 
existing prostate cancer microarray datasets was analyzed by 
setting a threshold value for gene rank at 10% and P<0.05.
Results
Evaluation of YY1 and DR5 protein expression in human 
prostate cancer tissues. Using immunohistochemical analysis, 
the YY1 and DR5 expression in PCa tissue microarray 
samples was examined. The expression of YY1 (Fig. 1Aa 
and b; Fig. 1Ba and b) and DR5 (Fig. 1Ac and d; Fig. 1Bc and 
d) in human PCa tissues were examined in the PIN and malig-
nant glandular epithelium (Figs. 1 and 2, respectively). YY1 
was expressed predominantly in the nucleus and diffusely in 
the cytoplasm. DR5 was expressed on the membrane and in 
the cytoplasm. The expression of YY1 in the PIN samples 
was weak and predominantly localized to the cytoplasm. By 
contrast, the DR5 expression in the PIN samples was detected 
in the membrane and in the cytoplasm. In tumor samples, the 
YY1 expression was directly proportional to the malignant 
grade, whereby the highest expression was observed in HG PCa 
as compared with the expression in the LG PCa (Fig. 2Aa and 
b). By contrast, the DR5 expression was inversely proportional 
to the tumor grade (low in HG PCa and high in LG PCa) 
(Fig. 2Ac and d).
Overexpression of YY1 and dowregulation of DR5 in PCa 
tissues. The expression of YY1 and DR5 was quantified by 
semiquantitative and quantitative assessments (Fig. 2B). There 
was a significant difference in the expression of YY1 between 
the LG PIN and HG PIN (Fig. 2Ba). In addition, there was 
a significant difference in the DR5 expression between the 
LG PIN and HG PIN samples (Fig. 2Bb) (P=0.001). YY1 
was significantly elevated in PCa tissues as compared with 
the PIN tissues. YY1 expression was barely  detectable in PIN 
tissues and was significantly increased (P<0.001, ANOVA) 
with an increase in tumor grade. This observation was similar 
in both the density quantification (Fig. 2Aa) and positive cell 
counts (nuclear) (Fig. 2Bc). An opposite effect was observed 
in the DR5 expression, whereby both the density of staining 
(Fig. 2Ab) and the positive cell counts (membrane) (Fig. 2Bd) 
were significantly decreased (P<0.001, ANOVA) as a function 
of the tumor grade. The highest levels of expression were 
observed in the PIN samples (Fig. 2Ac and d).
Inverse correlation between DR5 and YY1 expressions in 
PCa tissues. A Pearson's analysis was performed, based on 
the YY1 and DR5 expression in all of the tumor samples. The 
expression levels of YY1 and DR5 were found to be inversely 
correlated in both the LG PCa (P<0.036, r Pearson=-0.406) 
and HG PCa (P<0.0001, r Pearson=�0.611) samples (Table I).
Bioinformatic analyses of YY1 and TNFRSF10B (DR5) gene 
expression in prostate adenocarcinoma. Analysis of the 
TNFRSF10B (DR5) expression levels in different prostate 
tumors was performed using a public data set of microarrays 
retrieved from the Oncomine database and gene expression 
Omnibus, derived from the published analysis reported by 
Vanaja et al (28) and Wallace et al (29). The microarray data 
included 69 prostate adenocarcinomas and were compared 
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Figure 1. YY1 and DR5 expression in PIN and PCa in tissue microarray constructions. (A) Immunohistochemical staining for YY1 and DR5 in 
LG PIN and HG PIN samples. (a) LG PIN tissue showed weak nuclear and cytoplasmic epithelial staining of glandular cells. (b) HG PIN tissue 
showed frequently higher staining. Scoring was derived from the nuclear expression. (c) LG PIN tissue showed high cytoplasmic membrane staining 
of glandular cells. (d) HG PIN tissue showed frequently high staining. Scoring was derived from the cytoplasmic membrane staining expression. 
(B) Immunohistochemical staining for YY1 and DR5 in LG PCa and HG PCa samples. (a) LG PCa tissue showed moderate nuclear epithelial staining 
of glandular cells. (b) HG PCa tissue showed frequently strong nuclear epithelial staining of glandular cells. (c) LG PCa tissue showed weak cytoplasmic 
membrane staining of glandular cells. (d) HG PCa tissue showed the weakest to absent staining. Scoring was derived from the cytoplasmic staining expres-
sion. Magnification, x100 with x400 inserts. YY1, Yin Yang 1; DR5, death receptor 5; LG PCa, low grade prostate carcinoma; HG PCa, high grade prostate 
carcinoma; LG PIN, low grade prostatic intraepithelial neoplasia; HG PIN, high grade prostatic intraepithelial neoplasia.
  A
  B
  a   b
  c   d
  a   b
  c   d
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Figure 2. Expression and distribution of YY1 and DR5 in PIN and PCa in TMAs stratified by histological category. (A) The YY1 IOD and nuclear staining 
expression, and the DR5 IOD and DR5 protein expression in the cytoplasm and membrane, determined by immunohistochemistry, are shown as means 
represented as a bar graph, from the data of 270 informative tissue microarray spots containing NL (n=54), LG PIN (n=20), HG PIN (n=19), LG PCa (n=27), 
and HGPCa (n=27). (a) The mean YY1 IOD was significantly higher in the LG PCa (IOD=3675, P<0.001) and highest in the HG PCa (IOD=9042 P<0.001) as 
compared with the LG PIN (IOD=45) and the HG PIN (IOD=332). (b) The mean DR5 IOD was significantly lower in the LG PCa (IOD=3675 P<0.001) and 
significantly lower or absent in the HG PCa (IOD=9042, P<0.001) as compared with the LG PIN (IOD=45) and the HG PIN (IOD=332). (c) The mean YY1 
expression in nuclear staining was significantly higher in the LG PCa (IOD=3675, P<0.001) and highest in the HGPCa (IOD=9042, P<0.001) as compared 
with the LG PIN (IOD=45) and the HG PIN (IOD=332). (d) The mean DR5 expression in the cytoplasm membrane was significantly lower in the LG PCa 
(IOD=3675, P<0.001) and significantly lower or absent in the HG PCa (IOD=9042, P<0.001) as compared with the LG PIN (IOD=45) and the HG PIN 
(IOD=332). (B) YY1 and DR5 boxplots on the PIN and the PCa of different degrees in the TMAs, stratified by histological category. The distribution of the 
study population into different groups is represented graphically. (a) YY1 IOD distribution in the LG PIN, HG PIN, LG PCa and HG PCa. Both the PIN box 
plots are short since the YY1 IOD had a homogeneous distribution and minimal dispersion of cases. The YY1 IOD was low in both groups. The YY1 IOD 
expression in the PCa groups had a box plot greater than the PIN groups. The YY1 IOD was higher in both groups. The LG PCa box plot was less large, 
with a negative asymmetrical distribution, indicating that the majority of the measurements were lower than the HG PCa, but higher than the PIN groups. In 
addition, there was a low dispersion due to the homogeneity of the measurements. The HG PCa box plot had a positive asymmetrical distribution, meaning 
that the majority of the measurements were higher than those of the other groups. All the differences were statistically significant with P<0.0001. (b) DR5 IOD 
distribution in LG PIN, HG PIN, LG PCa and HG PCa. Both PIN box plots were shorter than those of the YY1 IOD, most markedly in the HG PIN group, 
where measures were greater. The dispersion in both groups was minimal and although there was asymmetry, this indicated that the measurements were 
homogeneous. The DR5 IOD expression in the PCa groups was very low, with a low dispersion, and a symmetrical and homogeneous distribution, which was 
due to low or absent expression. All differences were statistically significant with P<0.0001. *P=0.002 and **P=0.01. YY1 Yin Yang 1; Dr5, death receptor 5; 
PIN, prostatic intraepithelial neoplasia; PCa, prostate carcinoma; TMA, tissue microarray constructions; IOD, integrated optical density; LG PCa, low grade 
prostate carcinoma; HG PCa, high grade prostate carcinoma; NL, normal prostate. 
  B
  A
  a
  b  a
  d  c
  b
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with 20 samples from the prostate gland. In addition, YY1 
and DR5 gene expression from the prostate adenocarcinoma 
samples were analyzed in the same data sets and compared 
with the prostate gland. The tumors showed low expression 
of DR5 as compared with the normal tissues (P=0.05 or 0.02, 
respectively). A higher expression of YY1 was observed in the 
same data sets as compared with the normal tissues (P<0.05) 
(Fig. 3). An inverse correlation of expression was observed 
between DR5 and YY1 in PCa. These findings were concor-
dant with other database and gene expression analyses (30‑33).
Discussion
The present study has shown for the first time, to the best of 
our knowledge, the underexpression of DR5 in prostate cancer 
cell lines and patient-derived tumor tissues. The transcriptional 
regulation of DR5 was previously reported to be, at least in part, 
due to the repressor activity of YY1 (25). The present study 
therefore hypothesized that the transcriptional regulation of 
DR5 in human PCa would additionally be negatively regulated 
through the overexpression of YY1. The data of the present study 
Figure 3. Bioinformatics analysis. The analysis of YY1 and DR5 mRNA expression levels in the prostate carcinoma was performed using a public dataset 
of microarrays retrieved from the Oncomine™ database and gene expression Omnibus. (A) Relative YY1 expression in normal and malignant cells. 
(B) Relative DR5 expression in normal and malignant cells. The Oncomine box plot of YY1 and DR5 expression levels are shown as boxed quartiles (median, 
25th, and 75th percentile) and whiskers (minimum and maximum). *P<0.05 by one‑way analysis of variance. DR5, death receptor 5; YY1, Yin Yang 1.
Table I. YY1 and DR5 expression and their correlation in PCa, LG PCa and HG PCa.
  PCa LG PCa HG PCa
 IOD n=54 n=27 n=27
YY1 Median 5857.44 3676 8038
 range 2470‑12446 2471‑9622 3975‑12446
 S.D. 3253 1429 3107
 Median 4570 3481 9128
 CI 4969 3111 6810
DR5 Median 132 193 60
 range 38‑310 75‑310 38‑73
 S.D. 84 78.3 9
 Median 89 205 61
 CI 109 162 55
r Pearson YY1/DR5  �0.648 �0.406 �0.611
P-value  0.0001 0.036 0.001
P-values were determined by the Pearson χ2 test Yates continuity correction. The Pearson correlation was established using the percentage 
of nuclear YY1‑positive and membrane protein DR5‑positive specimens. Distribution of study population in PC, LG PCa and HG PCa. The 
correlation between YY1 and DR5 in PCa is ‑0. 648 with P=0.0001, in LG PCa is ‑0.406 (P=0.306) and in HGPCa is ‑0.611 (P=0.001). PCa, 
prostate carcinoma; LG PCa, low grade prostate carcinoma, Gleason scores 2 to 5; HG PCa, high grade prostate carcinoma, Gleason scores 6 to 
10. DR5, death receptor 5; YY1, Yin Yang 1; S.D., standard deviation; IOD, integrated optical density; PIN, prostatic intraepithelial neoplasia; 
CI, confidence interval.
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confirmed this hypothesis and demonstrated an inverse correla-
tion between the expression of DR5 and YY1. The experimental 
findings were corroborated by bioinformatic analyses. These 
data suggested that the expression levels of DR5 and YY1 in 
PCa may be novel prognostic factors in the progression of PCa.
The targeting of DR5 by TRAIL or anti‑DR5 monoclonal 
antibodies has been the focus of various clinical trials in clinical 
cancers (34-36). The approach to inhibit the repression of DR5 
through targeting YY1 will result in the upregulation of DR5 
and its response to TRAIL-induced apoptosis. We have previ-
ously demonstrated that the inhibition of YY1 by YY1‑specific 
siRNA in PCa cells resulted in sensitization of PCa cells to 
TRAIL apoptosis (37). It has been additionally shown that 
several anticancer agents overcome resistance to Apo2L/TRAIL 
through the upregulation of DR5 in malignant cells (25,38). In 
addition, the lower expression of DR5 has been noted in various 
types of cancer, including breast (39), lung (40), colorectal (41) 
and esophageal (42) cancers. Gene silencing of DR5 and DR4 
was shown to abolish TRAIL-induced apoptosis (43).
Of note, the expression levels of DR5 have been described 
as a potentially useful prognostic marker in various cancers, 
including melanoma, where the decrease in DR5 expression 
was identified to be correlated with the progression as well 
as metastasis of the disease (20). Furthermore, DR5 expres-
sion was shown to be negatively correlated with the overall 
survival of breast cancer patients (22). DR5, however, was 
not found to be a significant prognostic marker in cervical or 
colon cancers (22,23). These observations suggested that the 
prognostic value of DR5 may be cancer type-specific. In PCa, 
the significance of DR5 expression had not been previously 
explored and the present findings suggested that it may be a 
significant novel prognostic marker in the progression of PCa.
The transcription factor YY1 is expressed in normal 
tissues and is upregulated in various types of cancer, including 
PCa, with positive and negative regulatory effects on gene 
expression. Elevated YY1 expression is correlated with the 
development of PIN and advanced prostate cancer (44,45). The 
results of the present study regarding the expression of YY1 
and its correlation with the tumor grade are consistent with 
previous findings, which have linked higher YY1 expression 
to tumors, as compared with benign tissues.
In the present study, it was shown that YY1 was over-
expressed in tumor samples as compared with PIN. The 
overexpression gradually increased with higher tumor grades 
(Fig. 2A and B). By contrast, DR5 was considerably higher in 
PIN as compared to tumors. This downregulation of DR5 in the 
tumors decreased further with increasing tumor grade (Figs. 1 
and 2). In addition, Pearson's analysis demonstrated an inverse 
correlation between the expression of YY1 and DR5 in PCa 
tissues (Fig. 3). This finding is consistent with the hypothesis 
that YY1 negatively regulates DR5 and this inverse correlation 
in PCa patient samples has an important implication in the 
development of this disease.
High DR5 expression has been linked to TRAIL‑mediated 
apoptosis (15,25-27). DR5 expression was shown to be low in the 
tumors as compared with PIN, which suggested that the tumor 
cells may be resistant to TRAIL-mediated apoptosis. This is 
relevant since the TRAIL-DR5-mediated apoptotic pathway is 
involved in the immune‑mediated apoptosis signaling response 
by cytotoxic T lymphocytes and natural killer cells (46). 
These results additionally suggested a mechanism whereby 
patient tumors with high YY1 expression and, therefore, low 
DR5 expression (repressed by YY1), would experience higher 
apoptosis resistance to both immune and chemotherapeutic 
drugs and, consequently, develop tumors of higher grades as a 
consequence of tumor unresponsiveness to therapy.
The present findings have only examined the expression 
of DR5 in PCa and several reports have demonstrated that 
DR5 is the preferential receptor‑inducing signal for TRAIL 
apoptosis (25,27,39). The expression of DR4 and its role in 
TRAIL-induced apoptosis, however, cannot be ruled out. The 
expression of DR5 and DR4 is reduced in prostate tumors 
in comparison with that in benign tissues. Low expression 
of death receptors suggests resistance to apoptosis and, thus, 
increased tumorigenesis. However, YY1 has not been shown 
to regulate DR4 thus far to the best of our knowledge (47). 
Additional studies are therefore required to determine the role 
of DR4 in PCa and its clinical significance.
In conclusion, the present study demonstrated the clinical 
significance of DR5 downregulation in PCa and its inverse 
correlation with the expression of YY1. In addition, these data 
suggest a potential prognostic significance of both DR5 and 
YY1 in the progression of PCa.
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